- Home
- INCY vs ELS Comparison
INCY vs ELS Comparison
Compare INCY & ELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ELS
- Stock Information
- Founded
- INCY 1991
- ELS 1992
- Country
- INCY United States
- ELS United States
- Employees
- INCY N/A
- ELS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ELS Real Estate Investment Trusts
- Sector
- INCY Health Care
- ELS Real Estate
- Exchange
- INCY Nasdaq
- ELS Nasdaq
- Market Cap
- INCY 13.4B
- ELS 12.4B
- IPO Year
- INCY 1993
- ELS 1993
- Fundamental
- Price
- INCY $65.06
- ELS $63.57
- Analyst Decision
- INCY Hold
- ELS Buy
- Analyst Count
- INCY 19
- ELS 10
- Target Price
- INCY $72.67
- ELS $73.90
- AVG Volume (30 Days)
- INCY 1.8M
- ELS 1.4M
- Earning Date
- INCY 04-29-2025
- ELS 07-21-2025
- Dividend Yield
- INCY N/A
- ELS 3.24%
- EPS Growth
- INCY N/A
- ELS 5.86
- EPS
- INCY 0.10
- ELS 1.94
- Revenue
- INCY $4,413,226,000.00
- ELS $1,537,798,000.00
- Revenue This Year
- INCY $13.29
- ELS $1.93
- Revenue Next Year
- INCY $10.43
- ELS $2.94
- P/E Ratio
- INCY $592.09
- ELS $32.75
- Revenue Growth
- INCY 17.13
- ELS 1.94
- 52 Week Low
- INCY $53.56
- ELS $58.86
- 52 Week High
- INCY $83.95
- ELS $76.60
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- ELS 46.99
- Support Level
- INCY $63.51
- ELS $62.34
- Resistance Level
- INCY $66.26
- ELS $64.58
- Average True Range (ATR)
- INCY 1.60
- ELS 1.13
- MACD
- INCY 0.32
- ELS -0.03
- Stochastic Oscillator
- INCY 83.12
- ELS 52.19
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.